Consistently, increasing evidence implicated that sodium-glucose cotransporter inhibitors (SGLT2i) as an add-on therapy to insulin showed a positive effect on improving glycemic control in patients with T1DM [115–117]; however, SGLT2i were correlated with higher odds of diabetic ketoacidosis [118], which weakened the benefits of SGLT2is on glycemic control. The gene discussed is INS; the disease is type 1 diabetes mellitus.